News | June 08, 2026
Roche signs up to $2.3 billion deal with Nurix for BTK degrader Bexobrutideg
The agreement underscores Roche’s commitment to advancing innovative therapies for blood cancers and other serious diseases
The agreement underscores Roche’s commitment to advancing innovative therapies for blood cancers and other serious diseases
Community healthcare initiatives reach a milestone year, with services spanning 90 districts, 22 states, and over 70 lakh cumulative beneficiaries since 2006
Exclusive Asia-Pacific licensing agreement for Bejescin strengthens the company’s nephrology and autoimmune disease portfolio
The drug currently approved for chronic kidney disease (CKD) associated with type 2 diabetes, may benefit a much broader group of patients than previously recognized
Teva said the launch strengthens its biosimilars strategy and expands access to biologic medicines across Europe
Targeting deadly drug-resistant acinetobacter infections
The approval is expected to support the company’s presence in regulated international markets and further strengthen its position as a reliable pharma manufacturing partner
The facility sets a new benchmark in respiratory diagnostics
First-in-class treatment of life-threatening, drug-resistant Acinetobacter baumannii infections advancing toward Phase II clinical proof-of-concept
Novel fluorescent nanosensor enables real-time detection of indole-3-propionic acid (IPA), paving the way for faster gut health screening, point-of-care diagnostics, and wearable monitoring devices
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
